0001209191-12-007781.txt : 20120206
0001209191-12-007781.hdr.sgml : 20120206
20120206161345
ACCESSION NUMBER: 0001209191-12-007781
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120202
FILED AS OF DATE: 20120206
DATE AS OF CHANGE: 20120206
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139-4242
BUSINESS PHONE: 6165776000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silva Paul M
CENTRAL INDEX KEY: 0001446372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 12573778
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0304
4
2012-02-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001446372
Silva Paul M
C/O VERTEX PHARMACEUTICALS INCORPORATED
130 WAVERLY ST
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Corp Controller
Common Stock
2012-02-02
4
A
0
4500
0.01
A
13000
D
Common Stock
1380
I
401(k)
Stock Option
37.86
2012-02-02
4
A
0
18000
0.00
A
2012-05-02
2022-02-01
Common Stock
18000
18000
D
Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.
Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.
Valerie L. Andrews, Attorney-In-Fact
2012-02-06